Evidence map›Paper›PMID 26585240›Full record

ReviewDer Internist2015

[Molecular tumour therapy].

C Michel, A Neubauer, A Burchert

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

C MichelKlinik für Innere Medizin, Schwerpunkt Hämatologie, Onkologie, Immunologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, und Philipps-Universität, Baldingerstr. 1, 35043, Marburg, Deutschland.
A NeubauerKlinik für Innere Medizin, Schwerpunkt Hämatologie, Onkologie, Immunologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, und Philipps-Universität, Baldingerstr. 1, 35043, Marburg, Deutschland.
A BurchertKlinik für Innere Medizin, Schwerpunkt Hämatologie, Onkologie, Immunologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, und Philipps-Universität, Baldingerstr. 1, 35043, Marburg, Deutschland. burchert@staff.uni-marburg.de.
Universitätsklinikum Gießen und Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, molecular tumour therapy has dramatically improved the treatment of various types of cancer. Molecular therapy is expected to attack malignant cells more specifically with fewer side effects than conventional chemotherapy. Both kinase inhibitors and monoclonal antibodies are key components of today's molecular cancer therapy. These substances cannot fully overcome the major tumour-biological problems, e.g. therapy resistance. However, as can be vividly seen with the example of immune checkpoint inhibitors, the rational design of molecularly designed drugs will considerably change therapeutic practice in oncology, albeit at the expense of exponentially growing health care costs.

Indexed as

Antineoplastic AgentsHumansMolecular Targeted TherapyNeoplasmsAntineoplastic AgentsAntibodies, monoclonalDrug resistance, neoplasmImmunomodulationProtein kinase inhibitorsToxicity

Identifiers

PMID26585240
OpenAlexW2179312046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.